Does A2023 require prior authorization?

No, A2023 does not require prior authorization (high confidence). Covered without prior authorization.

What is the Medicare reimbursement rate for A2023?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

No Prior Auth Required

Covered without prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

This billing and coding article references Local Coverage Determination LCD L39624 for coverage and documentation requirements for amniotic and placental-derived product injections/applications for musculoskeletal (non-wound) indications; the LCD text was not provided so specific documentation requirements cannot be extracted.

Coverage applies when the amniotic or placental-derived product injection/application meets the reasonable and necessary requirements of Local Coverage Determination L39877.
Amniotic and placental-derived product injections/applications are covered only when they meet the reasonable and necessary clinical requirements specified in LCD L39879 (Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound).
Use of acellular human dermal allograft in rhinoplasty
Healing septal perforations using acellular dermis as bioscaffold
Artiss is approved for attachment of skin grafts onto burn patients (clinical trial basis described).
AlloSkin: As an allogeneic human, cadaver-derived skin graft for the management of traumatic skin wounds and burn wounds if the wound is too large for autograft. (Note: not AlloSkin AC or AlloSkin RT, which are different products).

WPS-J5-L39624, Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

A59434, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

WPS-J8-L39624, Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

FIRST_COAST-L39877, Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

A59764, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

NOVITAS-JH-L39879, Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

A59766, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

NOVITAS-JL-L39879, Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

BCBSMT-SUR704.012, Bioengineered Skin and Soft Tissue Substitutes

AETNA-CPB-0244, Skin and Soft Tissue Substitutes

BCBSOK-SUR704.012, Bioengineered Skin and Soft Tissue Substitutes

BCBSNM-SUR704.012, Bioengineered Skin and Soft Tissue Substitutes

AMBETTER-CP.MP.185, Skin and Soft Tissue Substitutes for Diabetic Foot Ulcers and Venous Leg Ulcers

BCBSIL-SUR704.012, Bioengineered Skin and Soft Tissue Substitutes

Ask Backwork about documentation requirements, denial risks, or coverage in your state.